Research

*July 2022* Dr. Joel Neal, MD, PhD discusses different cases of EGFR+ lung cancer patients. This is generally directed to physicians but also very informative for patients who want to educate themselves about what current treatments doctors are recommending. Watch the video here.

*July 2022* Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to Marina Garassino, MD. Single-agent osimertinib (Tagrisso) remains the standard of care for…

*July 2022* Although it is known that anti-PD1/L1 monotherapy does not render significant benefit in patients with EGFR-mutant lung adenocarcinoma, whether the addition of anti-PD1/L1 therapy to chemotherapy can enhance chemotherapy efficacy for TKI-refractory EGFR-mutant lung adenocarcinoma patients is not clear. To address this question, we retrospectively analyzed a cohort…

*July 2022* Introduction BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. Methods From October 2016 to May 2020, patients with advanced NSCLC for whom next-generation sequencing detected mutations of both BRAF and…

*July 2022* — A roundtable of experts predict what the future holds for treatment of the disease  New clinical research unveiled at the recent American Society of Clinical Oncology (ASCO) annual meeting has the potential to significantly alter the treatment of lung cancer. But what will be the innovations we…

*July 2022* Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression. Benjamin P. Levy, MD, Chaitali Nangia, MD, Patty and George Hoag Cancer Center, Jessica Donington, MD, MSCR, Jonathan Riess, MD, Alexander Spira, MD, PhD, FACP, Heather Wakelee,…

*June 2022* During this event, information about EGFR-mutant lung cancer, research advances, symptom management, as well as hearing from patients and caregivers were discussed.  Watch the webcast here.

*June 2022* John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements. An important exception to the use of PD-L1inhibitors as first-line therapy is for patients with oncogenic drivers. This is most strongly the case with…